November 22: The Week in Cancer News
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
Progress Against Cancer
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
Complications can affect men years after prostate cancer treatment, and many people eligible for lung cancer screening do not get it.
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone. In some cases of advanced esophageal cancer that are considered to...
Early initiation of palliative care leads to fewer hospital admissions, and surgery that removes fewer lymph nodes is effective for localized muscle-invasive bladder cancer.
Long-term monitoring can catch side effects in childhood cancer survivors, and breast cancer screening rates remain low among transgender people.
The therapeutic was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to asciminib (Scemblix) for adults with newly diagnosed, Philadelphia chromosome (Ph)-positive...
Asian American and Pacific Islander women face rising rates of early-onset breast cancer, and the risk for dying of COVID-19 is twice as high in people living with cancer.
Animals with longer gestation times may have fewer cancers, but the way traits relate to cancer risk is complex. Cancer occurs in animals as well as in humans, at widely varying rates among different...
The FDA approved the claudin 18.2-targeted therapy Zolbetuximab-clzb for some gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved zolbetuximab-clzb (Vyloy) plus a chemotherapy regimen consisting of fluoropyrimidine- and platinum-containing...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now